Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ILK-IN-2 (OSU-T315) is a novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 66.00 | |
2 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 165.00 | |
10 mg | In stock | $ 216.00 | |
25 mg | In stock | $ 275.00 | |
50 mg | In stock | $ 339.00 | |
100 mg | In stock | $ 493.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 232.00 |
Description | ILK-IN-2 (OSU-T315) is a novel potent, orally active ILK (integrin-linked kinase) inhibitor with IC50 of 0.6 μM. |
In vitro | OSU-T315 exhibited high in vitro potency against a panel of prostate and breast cancer cell lines (IC(50), 1-2.5 μM), while normal epithelial cells were unaffected. OSU-T315 facilitated the dephosphorylation of Akt at Ser-473 and other ILK targets, including glycogen synthase kinase-3β and myosin light chain. Moreover, OSU-T315 suppressed the expression of the transcription/translation factor YB-1 and its targets HER2 and EGFR in PC-3 cells, which could be rescued by the stable expression of constitutively active ILK [1]. The cytotoxicity of OSU-T315 in normal B or T cells was significantly lower (LC50 > 10 μM). OSU-T315 had the effect of dose-dependent cytotoxicity toward 2 CLL-derived cell lines, Mec-1 and OSU-CLL (LC50 of 2-3 μM in both) after 24-hour treatment [2]. |
In vivo | Athymic nude mice bearing established subcutaneous PC-3 tumors were treated with oral OSU-T315 once daily at 25 and 50 mg/kg or vehicle control. The daily administration of OSU-T315 at both doses was well tolerated. Treatment with oral OSU-T315 in either dose resulted in significant suppression of tumor growth relative to the vehicle control after 35 days of treatment (48% and 62% suppression for 25 and 50 mg/kg, respectively) [1]. |
Synonyms | OSU-T315 |
Molecular Weight | 533.59 |
Formula | C30H30F3N5O |
CAS No. | 1333146-24-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9 mg/mL (16.87 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ILK-IN-2 1333146-24-9 Cytoskeletal Signaling Integrin OSU-T315 inhibit ILK IN 2 ILKIN2 Inhibitor OSU-T-315 OSU-T 315 inhibitor